Sasanka Jayasuriya, MD
Interventional Cardiology · Milwaukee, WINPI 1891014148
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Shockwave Medical, Inc at 52.3% of the total. Reporting peaked in 2023 at $5,269 and has fallen 91.1% since, to $468 in 2025.
Across 65 payments — averaging $235.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$8K
- Cardiovascular Systems Inc.$2K
- Getinge USA Sales, LLC$1K
- Silk Road Medical, Inc.$767
- Medtronic$626
- Abbott$481
- plus $2K from 15 others
What the payments were for
- Consulting fees$3,97526%
- Speaking & faculty fees$6,97545%
- Travel & lodging$3522%
- Food & beverage$4,03426%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 6 | $8,028 |
| Cardiovascular Systems Inc. | 4 | $2,371 |
| Getinge USA Sales, LLC | 1 | $1,000 |
| Silk Road Medical, Inc. | 6 | $767 |
| Medtronic(2 entities) | 7 | $626 |
| Abbott | 9 | $481 |
| Abiomed | 4 | $384 |
| Boston Scientific | 5 | $378 |
| Edwards Lifesciences | 2 | $251 |
| Johnson & Johnson | 3 | $182 |
| Stryker | 5 | $150 |
| Livanova USA, Inc. | 1 | $142 |
| Bard Peripheral Vascular, Inc. | 1 | $104 |
| Philips North America LLC | 1 | $104 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $90 |
| Novartis | 3 | $57 |
| Angiodynamics, Inc. | 2 | $40 |
| Terumo Medical Corporation | 1 | $36 |
| Boehringer Ingelheim | 1 | $23 |
| Biotronik Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,028
- Diamondback Coronary$2,025
- ENROUTE Transcarotid Neuroprotection System$1,000
- CARDIOSAVE HYBRID, TYPE B PLUG$1,000
- ENROUTE Transcarotid Stent$567
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$298
- Impella$282
- Diamondback Peripheral$225
- Absolute Pro vascular stent system$202
- ENDURANT IIS$153
- LifeSPARC$142
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$138
- ENROUTE Transcarotid Stent System$136
- ENHANCE Transcarotid Peripheral Access Kit$136
- ENROUTE 0.014 Guidewire$136
- SUPERA$134
- Endurant$130
- COMET$116
- JETSTREAM$114
- Valiant Captivia$113
How this compares
$15,336 in reported general payments places this provider in the 75th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 179 | $207,809 |
| JardianceEmpagliflozin | 82 | $107,419 |
| EntrestoSacubitril/Valsartan | 67 | $103,748 |
| XareltoRivaroxaban | 67 | $81,477 |
| Repatha SureclickEvolocumab | 79 | $81,263 |
| FarxigaDapagliflozin Propanediol | 27 | $43,758 |
| Praluent PenAlirocumab | 31 | $29,044 |
| BrilintaTicagrelor | 24 | $28,859 |
| VascepaIcosapent Ethyl | 18 | $16,709 |
| Rosuvastatin Calcium | 708 | $8,233 |
| JanuviaSitagliptin Phosphate | 13 | $5,455 |
| Atorvastatin Calcium | 433 | $4,425 |
| Metoprolol Succinate | 327 | $4,413 |
| Ezetimibe | 252 | $3,896 |
| Potassium Chloride | 40 | $3,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $23 | $107,41982 claims |
| NovartisEntresto | $57 | $103,74867 claims |
| Johnson & JohnsonXarelto | $182 | $81,47767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Milwaukee
- Michael SalingerMilwaukee$216K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Montoya TaylorMilwaukee$48K
- Mina IskanderMilwaukee$41K
- Anna LarosaMilwaukee$38K
- Louie KostopoulosMilwaukee$26K
- Daniel JohnsrudMilwaukee$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.